Malaria transmission-blocking vaccines—how can their development be supported?
Malaria is a disease of poor countries. The development of malaria vaccines requires considerable investment, for which there is little commercial interest, particularly for transmission-blocking vaccines that have the public health objective of protecting communities from the spread of malaria rath...
Gespeichert in:
| Veröffentlicht in: | Nature medicine 2000-03, Vol.6 (3), p.241-244 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 244 |
|---|---|
| container_issue | 3 |
| container_start_page | 241 |
| container_title | Nature medicine |
| container_volume | 6 |
| creator | Carter, Richard Mendis, Kamini N Miller, Louis H Molineaux, Louis Saul, Allan |
| description | Malaria is a disease of poor countries. The development of malaria vaccines requires considerable investment, for which there is little commercial interest, particularly for transmission-blocking vaccines that have the public health objective of protecting communities from the spread of malaria rather than protecting individuals from the disease. Here, Carter
et al
. summarize the report of a committee of experts on the relevance and prospects for these vaccines. |
| doi_str_mv | 10.1038/73062 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_70943721</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A194209033</galeid><sourcerecordid>A194209033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c594t-b31e5912f4d59e9be40661fb340594f22304794b55cf25583e6f66492bab34c53</originalsourceid><addsrcrecordid>eNqN0l1r1jAUAOAiiptzf0GK4MCLznz3zZWM4cdgMvEL70qanvbNTJMuSafe-SP8hf4SMzvc3jFQcpHQPDk5PTlFsYvRPkZ09aymSJA7xTbmTFS4Rp_v5jWqV9VKcrFVPIjxFCFEEZf3i628gRDBZLt4-0ZZFYwqU1AujiZG413VWq-_GDeU50pr4yD--vFz7b-WWrkyrcGEsoNzsH4awaWyhTLO0-RDgu75w-Jer2yE3ct5p_j48sWHw9fV8cmro8OD40pzyVLVUgxcYtKzjkuQLTAkBO5bynKGrCeEIlZL1nKue8L5ioLohWCStCobzelOsbfEnYI_myGmJievwVrlwM-xqZFktCb4nxDXHAnOSIaPb8BTPweXf6LJ6WBCBLm4tlrQoCw0xvU-F04P4CAo6x30Jn8-wJIRJBGl2e_f4vPoYDT61gNPNw5kk-BbGtQcY3P0_t3_25NPm3bvml2DsmkdvZ1Tfu-4CZ8sUAcfY4C-mYIZVfjeYNRctFrzp9Wye3RZrrkdobumlt66ujHmLTdAuKrnzUjlAp1Kc4C_kdyY-xU1hGH6G8lk4Ew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223122625</pqid></control><display><type>article</type><title>Malaria transmission-blocking vaccines—how can their development be supported?</title><source>MEDLINE</source><source>Nature</source><source>SpringerNature Journals</source><creator>Carter, Richard ; Mendis, Kamini N ; Miller, Louis H ; Molineaux, Louis ; Saul, Allan</creator><creatorcontrib>Carter, Richard ; Mendis, Kamini N ; Miller, Louis H ; Molineaux, Louis ; Saul, Allan</creatorcontrib><description>Malaria is a disease of poor countries. The development of malaria vaccines requires considerable investment, for which there is little commercial interest, particularly for transmission-blocking vaccines that have the public health objective of protecting communities from the spread of malaria rather than protecting individuals from the disease. Here, Carter
et al
. summarize the report of a committee of experts on the relevance and prospects for these vaccines.</description><identifier>ISSN: 1078-8956</identifier><identifier>EISSN: 1546-170X</identifier><identifier>DOI: 10.1038/73062</identifier><identifier>PMID: 10700212</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>Animals ; Antibodies ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; commentary ; Disease transmission ; Genes ; Health aspects ; Humans ; Infections ; Infectious Diseases ; Insecticides ; Life Cycle Stages ; Malaria ; Malaria - prevention & control ; Malaria - transmission ; Malaria vaccine ; Malaria Vaccines ; Metabolic Diseases ; Molecular Medicine ; Mosquitoes ; Neurosciences ; Parasites ; Pharmaceutical industry ; Plasmodium - physiology ; Prevention ; Product development ; Public health ; Research Design ; Risk factors ; Tropical diseases ; Vaccines ; Vector-borne diseases</subject><ispartof>Nature medicine, 2000-03, Vol.6 (3), p.241-244</ispartof><rights>Nature America Inc. 2000</rights><rights>COPYRIGHT 2000 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Mar 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c594t-b31e5912f4d59e9be40661fb340594f22304794b55cf25583e6f66492bab34c53</citedby><cites>FETCH-LOGICAL-c594t-b31e5912f4d59e9be40661fb340594f22304794b55cf25583e6f66492bab34c53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/73062$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/73062$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,2727,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10700212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carter, Richard</creatorcontrib><creatorcontrib>Mendis, Kamini N</creatorcontrib><creatorcontrib>Miller, Louis H</creatorcontrib><creatorcontrib>Molineaux, Louis</creatorcontrib><creatorcontrib>Saul, Allan</creatorcontrib><title>Malaria transmission-blocking vaccines—how can their development be supported?</title><title>Nature medicine</title><addtitle>Nat Med</addtitle><addtitle>Nat Med</addtitle><description>Malaria is a disease of poor countries. The development of malaria vaccines requires considerable investment, for which there is little commercial interest, particularly for transmission-blocking vaccines that have the public health objective of protecting communities from the spread of malaria rather than protecting individuals from the disease. Here, Carter
et al
. summarize the report of a committee of experts on the relevance and prospects for these vaccines.</description><subject>Animals</subject><subject>Antibodies</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>commentary</subject><subject>Disease transmission</subject><subject>Genes</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious Diseases</subject><subject>Insecticides</subject><subject>Life Cycle Stages</subject><subject>Malaria</subject><subject>Malaria - prevention & control</subject><subject>Malaria - transmission</subject><subject>Malaria vaccine</subject><subject>Malaria Vaccines</subject><subject>Metabolic Diseases</subject><subject>Molecular Medicine</subject><subject>Mosquitoes</subject><subject>Neurosciences</subject><subject>Parasites</subject><subject>Pharmaceutical industry</subject><subject>Plasmodium - physiology</subject><subject>Prevention</subject><subject>Product development</subject><subject>Public health</subject><subject>Research Design</subject><subject>Risk factors</subject><subject>Tropical diseases</subject><subject>Vaccines</subject><subject>Vector-borne diseases</subject><issn>1078-8956</issn><issn>1546-170X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0l1r1jAUAOAiiptzf0GK4MCLznz3zZWM4cdgMvEL70qanvbNTJMuSafe-SP8hf4SMzvc3jFQcpHQPDk5PTlFsYvRPkZ09aymSJA7xTbmTFS4Rp_v5jWqV9VKcrFVPIjxFCFEEZf3i628gRDBZLt4-0ZZFYwqU1AujiZG413VWq-_GDeU50pr4yD--vFz7b-WWrkyrcGEsoNzsH4awaWyhTLO0-RDgu75w-Jer2yE3ct5p_j48sWHw9fV8cmro8OD40pzyVLVUgxcYtKzjkuQLTAkBO5bynKGrCeEIlZL1nKue8L5ioLohWCStCobzelOsbfEnYI_myGmJievwVrlwM-xqZFktCb4nxDXHAnOSIaPb8BTPweXf6LJ6WBCBLm4tlrQoCw0xvU-F04P4CAo6x30Jn8-wJIRJBGl2e_f4vPoYDT61gNPNw5kk-BbGtQcY3P0_t3_25NPm3bvml2DsmkdvZ1Tfu-4CZ8sUAcfY4C-mYIZVfjeYNRctFrzp9Wye3RZrrkdobumlt66ujHmLTdAuKrnzUjlAp1Kc4C_kdyY-xU1hGH6G8lk4Ew</recordid><startdate>20000301</startdate><enddate>20000301</enddate><creator>Carter, Richard</creator><creator>Mendis, Kamini N</creator><creator>Miller, Louis H</creator><creator>Molineaux, Louis</creator><creator>Saul, Allan</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20000301</creationdate><title>Malaria transmission-blocking vaccines—how can their development be supported?</title><author>Carter, Richard ; Mendis, Kamini N ; Miller, Louis H ; Molineaux, Louis ; Saul, Allan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c594t-b31e5912f4d59e9be40661fb340594f22304794b55cf25583e6f66492bab34c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animals</topic><topic>Antibodies</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>commentary</topic><topic>Disease transmission</topic><topic>Genes</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious Diseases</topic><topic>Insecticides</topic><topic>Life Cycle Stages</topic><topic>Malaria</topic><topic>Malaria - prevention & control</topic><topic>Malaria - transmission</topic><topic>Malaria vaccine</topic><topic>Malaria Vaccines</topic><topic>Metabolic Diseases</topic><topic>Molecular Medicine</topic><topic>Mosquitoes</topic><topic>Neurosciences</topic><topic>Parasites</topic><topic>Pharmaceutical industry</topic><topic>Plasmodium - physiology</topic><topic>Prevention</topic><topic>Product development</topic><topic>Public health</topic><topic>Research Design</topic><topic>Risk factors</topic><topic>Tropical diseases</topic><topic>Vaccines</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carter, Richard</creatorcontrib><creatorcontrib>Mendis, Kamini N</creatorcontrib><creatorcontrib>Miller, Louis H</creatorcontrib><creatorcontrib>Molineaux, Louis</creatorcontrib><creatorcontrib>Saul, Allan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carter, Richard</au><au>Mendis, Kamini N</au><au>Miller, Louis H</au><au>Molineaux, Louis</au><au>Saul, Allan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Malaria transmission-blocking vaccines—how can their development be supported?</atitle><jtitle>Nature medicine</jtitle><stitle>Nat Med</stitle><addtitle>Nat Med</addtitle><date>2000-03-01</date><risdate>2000</risdate><volume>6</volume><issue>3</issue><spage>241</spage><epage>244</epage><pages>241-244</pages><issn>1078-8956</issn><eissn>1546-170X</eissn><abstract>Malaria is a disease of poor countries. The development of malaria vaccines requires considerable investment, for which there is little commercial interest, particularly for transmission-blocking vaccines that have the public health objective of protecting communities from the spread of malaria rather than protecting individuals from the disease. Here, Carter
et al
. summarize the report of a committee of experts on the relevance and prospects for these vaccines.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>10700212</pmid><doi>10.1038/73062</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-8956 |
| ispartof | Nature medicine, 2000-03, Vol.6 (3), p.241-244 |
| issn | 1078-8956 1546-170X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70943721 |
| source | MEDLINE; Nature; SpringerNature Journals |
| subjects | Animals Antibodies Biomedical and Life Sciences Biomedicine Cancer Research commentary Disease transmission Genes Health aspects Humans Infections Infectious Diseases Insecticides Life Cycle Stages Malaria Malaria - prevention & control Malaria - transmission Malaria vaccine Malaria Vaccines Metabolic Diseases Molecular Medicine Mosquitoes Neurosciences Parasites Pharmaceutical industry Plasmodium - physiology Prevention Product development Public health Research Design Risk factors Tropical diseases Vaccines Vector-borne diseases |
| title | Malaria transmission-blocking vaccines—how can their development be supported? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T23%3A52%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Malaria%20transmission-blocking%20vaccines%E2%80%94how%20can%20their%20development%20be%20supported?&rft.jtitle=Nature%20medicine&rft.au=Carter,%20Richard&rft.date=2000-03-01&rft.volume=6&rft.issue=3&rft.spage=241&rft.epage=244&rft.pages=241-244&rft.issn=1078-8956&rft.eissn=1546-170X&rft_id=info:doi/10.1038/73062&rft_dat=%3Cgale_proqu%3EA194209033%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223122625&rft_id=info:pmid/10700212&rft_galeid=A194209033&rfr_iscdi=true |